# Phase 3 Triple Negative Breast Neoplasms trials: 32 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials in phase 3 for Triple Negative Breast Neoplasms that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Triple Negative Breast Neoplasms trials: 32 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/triple-negative-breast-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 19, 2026 | NCT07879911 | A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Triple Negative Breast Cancer | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879911) |
| August 12, 2026 | NCT07760844 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC | Fudan University | Phase 3 | Not yet recruiting | Breast Cancer, Triple Negative Breast Cancer (TNBC) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760844) |
| July 28, 2026 | NCT07729956 | A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Triple-Negative Breast Cancer (TNBC) | 436 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729956) |
| July 23, 2026 | NCT07723469 | Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery | SURGE Therapeutics | Phase 3 | Not yet recruiting | TNBC - Triple-Negative Breast Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723469) |
| July 1, 2026 | NCT07679360 | A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Recruiting | Triple Negative Breast Cancer | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679360) |
| June 25, 2026 | NCT07669610 | An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC | Fudan University | Phase 3 | Not yet recruiting | Breast Cancer, Triple Negative Breast Cancer (TNBC) | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669610) |
| April 29, 2026 | NCT07556848 | A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 3 | Not yet recruiting | Locally Advanced or Metastatic Triple-negative Breast Cancer | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07556848) |
| April 16, 2026 | NCT07533123 | A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard... | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 3 | Recruiting | Triple Negative Breast Cancer | 364 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07533123) |
| March 20, 2026 | NCT07486687 | Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab... | The Netherlands Cancer Institute | Phase 3 | Not yet recruiting | Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative... | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486687) |
| February 12, 2026 | NCT07407517 | Adjuvant Intensification for LAR | Fudan University | Phase 3 | Not yet recruiting | Breast Cancer Females, Triple Negative Breast Cancer (TNBC) | 904 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407517) |
| September 17, 2025 | NCT07178730 | NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early... | Women's Cancer Study Group GmbH | Phase 3 | Not yet recruiting | Breast Cancer, Triple-negative Breast Cancer | 765 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07178730) |
| August 8, 2025 | NCT07111832 | A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Recruiting | PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07111832) |
| May 13, 2025 | NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms | 2,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06966700) |
| March 21, 2025 | NCT06889688 | Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | Recruiting | Breast Cancer Stage IV, Triple -Negative Breast Cancer | 246 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06889688) |
| February 24, 2025 | NCT06841354 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Triple Negative Breast Neoplasms | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06841354) |
| January 28, 2025 | NCT06795503 | Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients | Fudan University | Phase 3 | Not yet recruiting | Triple-negative Breast Cancer | 1,462 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06795503) |
| January 10, 2025 | NCT06767527 | AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer | Akeso | Phase 3 | Recruiting | Triple-Negative Breast Cancer (TNBC) | 416 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06767527) |
| December 13, 2024 | NCT06732323 | A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Triple-Negative Breast Cancer (TNBC) | 504 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06732323) |
| October 4, 2024 | NCT06627712 | SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC | West China Hospital | Phase 3 | Recruiting | TNBC - Triple-Negative Breast Cancer | 318 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06627712) |
| September 23, 2024 | NCT06606730 | Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer | UNICANCER | Phase 3 | Recruiting | Breast Cancers, Triple Negative Breast Cancer (TNBC) | 2,454 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06606730) |
| August 1, 2024 | NCT06533384 | PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC | Guangdong Provincial People's Hospital | Phase 3 | Recruiting | Triple-negative Breast Cancer | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06533384) |
| May 1, 2024 | NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Triple-Negative Breast Cancer | 1,530 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06393374) |
| October 13, 2023 | NCT06081244 | NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) | Women's Cancer Study Group GmbH | Phase 3 | Recruiting | Triple Negative Breast Cancer | 348 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06081244) |
| August 21, 2023 | NCT05999149 | A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple... | Fudan University | Phase 3 | Recruiting | TNBC - Triple-Negative Breast Cancer | 424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05999149) |
| June 18, 2023 | NCT05909332 | Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) | Fudan University | Phase 3 | Recruiting | Breast Cancer, Triple Negative Breast Cancer | 764 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05909332) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 9 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 3 |
| Women's Cancer Study Group GmbH | 2 |
| [Suzhou Suncadia Biopharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd) | 2 |
| [Shanghai Henlius Biotech](https://specstream.ai/data/clinical-trials/company/shanghai-henlius-biotech) | 1 |
| [Gilead Sciences](https://specstream.ai/data/clinical-trials/company/gilead-sciences) | 1 |
| [Mabwell (Shanghai) Bioscience Co., Ltd.](https://specstream.ai/data/clinical-trials/company/mabwell-shanghai-bioscience-co-ltd) | 1 |
| [Jiangsu Alphamab Biopharmaceuticals Co., Ltd](https://specstream.ai/data/clinical-trials/company/jiangsu-alphamab-biopharmaceuticals-co-ltd) | 1 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 1 |
| Sun Yat-Sen University Cancer Center | 1 |
| Jina Pharmaceuticals Inc. | 1 |
| West China Hospital | 1 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 1 |
| SURGE Therapeutics | 1 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 1 |
| UNICANCER | 1 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 1 |
| The Netherlands Cancer Institute | 1 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| Guangdong Provincial People's Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 18 |
| Germany | 6 |
| United States | 6 |
| Belgium | 5 |
| France | 5 |
| Australia | 4 |
| Brazil | 4 |
| Italy | 4 |
| Japan | 4 |
| South Korea | 4 |
| Spain | 4 |
| United Kingdom | 4 |
| Argentina | 3 |
| Canada | 3 |
| Colombia | 3 |
| Czechia | 3 |
| Finland | 3 |
| Greece | 3 |
| Hong Kong | 3 |
| Israel | 3 |
| Malaysia | 3 |
| Poland | 3 |
| Turkey (Türkiye) | 3 |
| Chile | 2 |
| Denmark | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Cardiology practices in the United States](https://specstream.ai/data/businesses/cardiology-practices/united-states)
- [Importers in the United States](https://specstream.ai/data/businesses/importers/united-states)
- [Sand and gravel suppliers in the United States](https://specstream.ai/data/businesses/sand-and-gravel-suppliers/united-states)
- [Basque restaurants in the United States](https://specstream.ai/data/businesses/basque-restaurants/united-states)
- [Greek restaurants in the United States](https://specstream.ai/data/businesses/greek-restaurants/united-states)
- [Process servers in the United States](https://specstream.ai/data/businesses/process-servers/united-states)
